ELVN
VENTE TOTALE: 168 795 titres (~10 061 420,85 $ US)
- Insiders
- Derynck Mika K, Kunkel Lori Anne
- Total bought
- —
- Total sold
- $10,061,421
- Last activity
- 2026-08-04
- Last synced
-
2026-08-10 09:45:27
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-26
ELVN presents a deeply contradictory profile: a strong liquidity score (85) and a meaningful event catalyst (positive Phase 1 data, institutional accumulation) are severely undermined by near-zero fundamental health…
The first sentence of the analysis written for ELVN on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 28.662 | 19.989 | 10.278 | 8.003 | 19.237 | |
| Quick Ratio | 28.662 | 19.989 | 10.278 | 8.003 | 19.237 | |
| Solvency Ratio | -6.202 | -5.574 | -2.746 | -0.234 | -3.808 | |
| Cash Ratio | 5.969 | 7.799 | 3.867 | 7.775 | 19.125 | |
| Price To Earnings Ratio | -8.415 | -11.905 | -6.886 | -2.713 | -2.839 | |
| Price To Earnings Growth Ratio | 2.651 | 1.994 | 0.103 | -0.030 | 0.107 | |
| Forward Price To Earnings Growth Ratio | 2.651 | 1.994 | 0.103 | -0.030 | 0.107 | |
| Price To Earnings Diluted Ratio | -8.415 | -11.905 | -6.886 | -2.713 | -2.839 | |
| Price To Earnings Diluted Growth Ratio | 2.651 | 1.994 | 0.103 | -0.030 | 0.107 | |
| Price To Book Ratio | 1.899 | 3.418 | 2.001 | -1.331 | 0.658 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -12.385 | -14.462 | -8.010 | -3.127 | -3.639 | |
| Price To Operating Cash Flow Ratio | -12.413 | -14.471 | -8.029 | -3.187 | -3.675 | |
| Debt To Assets Ratio | 0.001 | 0.000 | 0.001 | 0.004 | 0.001 | |
| Debt To Equity Ratio | 0.001 | 0.000 | 0.001 | -0.004 | 0.001 | |
| Debt To Capital Ratio | 0.001 | 0.000 | 0.001 | -0.004 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.036 | 1.051 | 1.106 | -1.084 | 1.061 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.243 | -4.599 | -2.366 | -3.302 | -3.326 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.001 | 1.002 | 1.019 | 1.010 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -176.193 | 0.000 | -182.893 | -99.310 | -120.340 | |
| Capital Expenditure Coverage Ratio | -444.943 | -1,663.455 | -411.201 | -52.413 | -100.178 | |
| Dividend Paid And Capex Coverage Ratio | -444.943 | -1,663.455 | -411.201 | -52.413 | -100.178 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.485 | -10.568 | -5.501 | -0.722 | 1.606 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 28.662 | ▲8.673 | ▲11.428 |
| Quick Ratio | 28.662 | ▲8.673 | ▲11.428 |
| Solvency Ratio | -6.202 | ▼-0.629 | ▼-2.490 |
| Cash Ratio | 5.969 | ▼-1.830 | ▼-2.938 |
| Price To Earnings Ratio | -8.415 | ▲3.490 | ▼-1.864 |
| Price To Earnings Growth Ratio | 2.651 | ▲0.657 | ▲1.686 |
| Forward Price To Earnings Growth Ratio | 2.651 | ▲0.657 | ▲1.686 |
| Price To Earnings Diluted Ratio | -8.415 | ▲3.490 | ▼-1.864 |
| Price To Earnings Diluted Growth Ratio | 2.651 | ▲0.657 | ▲1.686 |
| Price To Book Ratio | 1.899 | ▼-1.520 | ▲0.570 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -12.385 | ▲2.077 | ▼-4.060 |
| Price To Operating Cash Flow Ratio | -12.413 | ▲2.058 | ▼-4.058 |
| Debt To Assets Ratio | 0.001 | ▲0.001 | ▼-0.001 |
| Debt To Equity Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Debt To Capital Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.036 | ▼-0.015 | ▲0.402 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.243 | ▲0.356 | ▼-0.676 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▲0.002 | ▼-0.005 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -176.193 | ▼-176.193 | ▼-60.446 |
| Capital Expenditure Coverage Ratio | -444.943 | ▲1218.512 | ▲89.495 |
| Dividend Paid And Capex Coverage Ratio | -444.943 | ▲1218.512 | ▲89.495 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.484 | ▲3.084 | ▼-2.951 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $872.6M | $1.06B | $492.0M | $102.2M | $70.3M | |
| Enterprise value | $774.1M | $935.0M | $392.2M | $27.0M | -$39.5M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -11.01x | -12.78x | -6.40x | -0.84x | 2.07x | |
| EV / Free cash flow | -10.99x | -12.77x | -6.38x | -0.83x | 2.05x | |
| EV / EBITDA | -7.49x | -10.57x | -5.50x | -0.72x | 1.61x | |
| Net debt / EBITDA | 0.95x | 1.40x | 1.40x | 2.01x | 4.46x | |
| Current ratio | 28.66x | 19.99x | 10.28x | 8.00x | 19.24x | |
| Income quality | 0.68x | 0.82x | 0.86x | 0.85x | 0.77x | |
| Graham net-net | $8 | $6 | $6 | -$14 | $13 | |
| Tax burden | 100.0% | 100.3% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $458.3M | $302.2M | $240.3M | $68.0M | $104.9M | |
| Invested capital | $458.7M | $302.7M | $241.3M | $69.6M | $105.9M | |
| Return on assets | -21.8% | -27.3% | -26.3% | -45.2% | -21.8% | |
| Operating ROA | -29.8% | -35.0% | -47.0% | -39.5% | -24.3% | |
| Return on tangible assets | -21.8% | -27.3% | -26.3% | -45.2% | -21.8% | |
| Return on equity | -22.6% | -28.7% | -29.1% | 49.0% | -23.2% | |
| Return on invested capital | -26.0% | -33.7% | -33.9% | -52.5% | -23.0% | |
| Return on capital employed | -26.0% | -33.7% | -34.0% | -52.7% | -23.0% | |
| Earnings yield | -11.9% | -8.4% | -14.6% | -36.8% | -35.2% | |
| Free cash flow yield | -8.1% | -6.9% | -12.5% | -32.0% | -27.5% | |
| Capex / Op. cash flow | -0.2% | -0.1% | -0.2% | -1.9% | -1.0% | |
| Capex / Depreciation | 60.1% | 13.9% | 50.2% | 284.7% | 166.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 2996d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -2996d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-17.6%EV / Sales n/aEV / EBITDA ▲+29.2%EV / Op. cash flow ▲+1.763Earnings yield ▼-0.035
Profitability
Return on equity ▲+0.062Return on assets ▲+0.056Return on invested capital ▲+0.077Return on capital employed ▲+0.077Operating ROA ▲+0.051Income quality ▼-0.144Tax burden ▼-0.003
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+8.673Net debt / EBITDA ▼-0.451Working capital ▲+156098000.000Invested capital ▲+156057000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+1140.8%EV / Sales n/aEV / EBITDA ▼-566.1%EV / Op. cash flow ▼-13.078Earnings yield ▲+0.233
Profitability
Return on equity ▲+0.006Return on assets ▲+0.001Return on invested capital ▼-0.030Return on capital employed ▼-0.030Operating ROA ▼-0.056Income quality ▼-0.095Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+9.425Net debt / EBITDA ▼-3.509Working capital ▲+353393000.000Invested capital ▲+352856000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-06 Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 70.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 681,715 shares of the company''s stock after acquiring an additional 282,822 shares during the quarter. Dimensional Fund Advisors LP
- 2026-08-05 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key Phase 3 trial design components Strong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030 BURLINGAME, Calif., Aug. 5, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
- 2026-08-01 Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 185.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 400,000 shares of the company''s stock after purchasing an additional 259,700 shares during the quarter. Enliven Therapeutics makes
- 2026-06-27 What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
- 2026-06-27 What to Know About OrbiMed''s $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Llc Orbimed''s total indirect holdings, reducing indirect ownership from 7,415,225 to 6,555,102 shares.
- 2026-06-15 Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters'' Option to Purchase Additional Shares BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters'' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven''s common stock less the $0.001 per share exercise price for each pre-funded warrant.
- 2026-06-11 Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
- 2026-06-11 Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven''s common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven''s common stock less the $0.001 per share exercise price for each pre-funded warrant.
- 2026-06-11 Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven''s common stock.
- 2026-06-11 Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript